Icrucumab
| Icrucumab | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Icrucumab is an experimental monoclonal antibody designed for the treatment of various types of cancer. It targets the vascular endothelial growth factor receptor 2 (VEGFR-2), which plays a key role in angiogenesis, the process by which tumors develop new blood vessels to sustain their growth.
Mechanism of Action[edit]
Icrucumab binds to VEGFR-2, inhibiting the receptor's activity. By blocking VEGFR-2, icrucumab prevents the signaling processes essential for the formation of new blood vessels in tumors. This inhibition of angiogenesis is intended to starve the tumor of nutrients and oxygen, thereby inhibiting its growth and potentially leading to tumor shrinkage.
Clinical Trials[edit]
The development of icrucumab has involved several clinical trials aimed at evaluating its efficacy and safety in treating various cancers. These studies have explored its use as both a single-agent therapy and in combination with other chemotherapy and targeted therapy agents. The outcomes of these trials are crucial for determining the potential of icrucumab as a viable therapeutic option in oncology.
Pharmacokinetics[edit]
The pharmacokinetic properties of icrucumab, including its absorption, distribution, metabolism, and excretion, are important in understanding its behavior in the human body. These characteristics influence the dosage regimen and administration strategy for the drug.
Safety and Efficacy[edit]
As with any experimental therapy, the safety and efficacy of icrucumab are of paramount importance. Clinical trials assess these aspects through various endpoints, including tumor response rate, progression-free survival, overall survival, and the incidence of adverse effects.
Future Directions[edit]
The future development of icrucumab will depend on the results of ongoing and future clinical trials. If successful, it could become a new treatment option for patients with certain types of cancer, potentially improving outcomes and quality of life.
See Also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
